Last updated: June 5, 2026

Back to directory

Lunit SCOPE medical AI product profile

Digital pathology AI suite from Lunit for precision-oncology research, biomarker discovery, IHC analysis, and selected pathologist-assistive workflows.

Screenshot of the official Lunit SCOPE product page
Digital pathology

Best fit

Teams evaluating AI pathology analysis for oncology biomarker programs, immunotherapy research, trial enrichment, or governed pathology AI pilots with module-specific intended-use review.

Primary use case
AI-powered digital pathology analysis for tumor microenvironment profiling, IHC quantification, PD-L1 scoring support, genotype prediction research, and biomarker development workflows
Audience
Pathology labs, biopharma translational teams, companion-diagnostic groups, oncology research teams, and digital pathology governance committees
Risk level
High
Pricing signal
Enterprise, research, and partnership pricing is not public; verify current module, integration, scanner, study, and regional commercial terms.
Official sources
6 official sources

Compare within workflow: Digital pathology · comparison shortlist · source index

Regulatory, privacy, evidence, and workflow lens

Product-specific review. These product-specific signals summarize what the cited sources imply before treating Lunit SCOPE as safe for a local clinical, operational, or research workflow.

Regulatory / FDASeparate every SCOPE module, version, geography, study purpose, and intended use before deployment; research-use-only language on SCOPE IO, GP, uIHC, and IHC Suite pages should not be treated as diagnostic authorization.
PrivacyReview whole-slide image transfer, platform integrations, support access, annotations, study metadata, product-service data, de-identified data handling, retention, international transfers, and customer-contract privacy terms.
EvidenceUse Lunit's publication library, module-specific validation materials, and local pilot data to test scanner mix, tissue and stain quality, cancer subtype, biomarker endpoint, reproducibility, pathologist agreement, and trial-readout impact.
WorkflowBest governed as a module-specific digital pathology and biopharma analysis workflow with pathologist, translational science, clinical-trial, privacy, and regulatory review before outputs inform patient selection or reports.

Where Lunit SCOPE fits

Lunit describes SCOPE as a precision-oncology digital pathology suite for H&E tumor microenvironment analysis, IHC biomarker strategy, genotype prediction, and PD-L1 quantification; its product pages label several SCOPE workflows as research use only and not for diagnostic procedures or decisions, while Lunit's publications and privacy materials provide evidence and data-handling context to verify before clinical or trial adoption.

Not for: Autonomous diagnosis, treatment selection, assuming all SCOPE modules are cleared for clinical use, or using research-use modules in diagnostic procedures or decisions.

What to verify before using Lunit SCOPE

Source links

Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.

Related medical AI products